SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-18-001386
Filing Date
2018-03-02
Accepted
2018-03-02 16:16:01
Documents
1
Period of Report
2018-02-28

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 5953
  Complete submission text file 0001562180-18-001386.txt   7359
Mailing Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Issuer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET, SUITE 1100 CAMBRIDGE MA 02142
Business Address
Dahan Michel (Reporting) CIK: 0001669737 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36352 | Film No.: 18662167